For the Media
Dr. Matthias Stephan is member of Fred Hutch's Clinical Research Division in the Program in Immunology. His research is focused on developing therapies that selectively modulate the immune system. Current studies involve injectable nanoparticle reagents to program T cells to attach tumors. His work is targeting melanoma, prostate, ovarian and pancreatic cancers.
Overview of Matthias Stephan's Research Focus
The Stephan laboratory are currently focused on (1) the development of an implantable device to eradicate tumor cells left behind after surgery, and (2) the design of polymeric nanoparticles that can rapidly program tumor-recognizing capabilities into lymphocytes in vivo.
Matthias Stephan - Brief Curriculum Vitae
Appointments, affiliations and researcher interests
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
Program in Immunology
Program researchers continue to develop ways to make immunity-boosting therapies even more effective. They are showing these treatments can induce remissions for patients with advanced tumors and are likely to have broad utility across many cancers.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.